Literature DB >> 21316815

"Lest we forget you--methylene blue...".

R Heiner Schirmer1, Heike Adler, Marcus Pickhardt, Eckhard Mandelkow.   

Abstract

Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse applications, both in medical treatments and as a staining reagent. In recent years there was a surge of interest in MB as an antimalarial agent and as a potential treatment of neurodegenerative disorders such as Alzheimer's disease (AD), possibly through its inhibition of the aggregation of tau protein. Here we review the history and medical applications of MB, with emphasis on recent developments.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316815     DOI: 10.1016/j.neurobiolaging.2010.12.012

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  96 in total

1.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.

Authors:  Sophie H Adjalley; Geoffrey L Johnston; Tao Li; Richard T Eastman; Eric H Ekland; Abraham G Eappen; Adam Richman; B Kim Lee Sim; Marcus C S Lee; Stephen L Hoffman; David A Fidock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

Review 2.  [Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets].

Authors:  M A Busche; M Staufenbiel; M Willem; C Haass; H Förstl
Journal:  Nervenarzt       Date:  2016-11       Impact factor: 1.214

Review 3.  Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Authors:  Narendran Annadurai; Khushboo Agrawal; Petr Džubák; Marián Hajdúch; Viswanath Das
Journal:  Cell Mol Life Sci       Date:  2017-06-20       Impact factor: 9.261

4.  Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

Authors:  Takashi Mori; Naoki Koyama; Tatsuya Segawa; Masahiro Maeda; Nobuhiro Maruyama; Noriaki Kinoshita; Huayan Hou; Jun Tan; Terrence Town
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

Review 5.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

6.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

7.  Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

Authors:  Tara L Spires-Jones; Taylor Friedman; Rose Pitstick; Manuela Polydoro; Allyson Roe; George A Carlson; Bradley T Hyman
Journal:  Neurosci Lett       Date:  2014-01-21       Impact factor: 3.046

8.  Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.

Authors:  Alex Crowe; Michael J James; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski; Carlo Ballatore; Kurt R Brunden
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

Review 9.  Structural and functional photoacoustic molecular tomography aided by emerging contrast agents.

Authors:  Liming Nie; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2014       Impact factor: 54.564

Review 10.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.